Zenyaku Kogyo To Take Over Rituxan Sales After Chugai Exits Rituxan Co-Promotion In Japan

Zenyaku Kogyo and Chugai Pharmaceutical have announced the termination of their co-promotion agreement in Japan for Rituxan (rituximab), effective September 3, 2026. The collaboration previously involved joint sales and medical information activities for the intravenous infusion product in 100 mg and 500 mg doses.

Following a strategic review of future sales policies, Chugai will discontinue its involvement in Rituxan’s commercialization after selling off its remaining inventory. From September 4, 2026, Zenyaku Kogyo will take over full responsibility for the product’s sales and the provision of medical information in Japan.

Both companies have stated that they will work closely to ensure a seamless transition of responsibilities. During this period, they will continue to focus on maintaining a stable supply of the therapy, delivering accurate medical information, and supporting its appropriate clinical use.

Rituxan, a monoclonal antibody widely used in the treatment of various autoimmune diseases and cancers, will continue to be available in the Japanese market under Zenyaku Kogyo’s sole management following the transition.